Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF- α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance

ConclusionsWe conclude that biosimilars of adalimumab and etanercept have equivalent effectiveness over a long period of time compared to their originator drugs, and also that the levels of disease activity after 6 months of tumor necrosis factor- α inhibitors (originator drugs and biosimilars) might predict the response to therapy at 4 years in patients with long-standing rheumatoid arthritis.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research